Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer

ErbB-3 and its ligand NRG-1β are key players in driving oncogenic signaling and resistance to therapy through the activation of the PI3K/Akt pathway. We have recently reported that EV20, a humanized anti-ErbB3 antibody, possesses a marked antitumor activity in a variety of human tumor models, includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghasemi, R, Rapposelli, I G, Capone, E, Rossi, C, Lattanzio, R, Piantelli, M, Sala, G, Iacobelli, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189962/
https://www.ncbi.nlm.nih.gov/pubmed/25133484
http://dx.doi.org/10.1038/oncsis.2014.31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189962/
https://www.ncbi.nlm.nih.gov/pubmed/25133484
http://dx.doi.org/10.1038/oncsis.2014.31

Ejemplares similares